DEUTSCHE BANK AG\ - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q1 2023$91,185
-58.5%
129,708
+33.4%
0.00%
Q4 2022$219,816
-16.1%
97,264
+18.7%
0.00%
Q3 2022$262,000
-59.9%
81,917
-52.4%
0.00%
Q2 2022$653,000
+104.1%
172,041
+190.4%
0.00%
Q1 2022$320,000
-60.1%
59,237
-0.3%
0.00%
Q4 2021$803,000
-29.5%
59,420
-6.3%
0.00%
-100.0%
Q3 2021$1,139,000
+305.3%
63,398
+286.1%
0.00%
Q2 2021$281,000
-48.6%
16,420
-39.9%
0.00%
Q1 2021$547,000
+122.4%
27,340
+88.5%
0.00%
Q4 2020$246,000
-80.5%
14,501
-80.9%
0.00%
-100.0%
Q3 2020$1,259,000
+65.7%
75,878
+131.2%
0.00%0.0%
Q2 2020$760,000
-88.3%
32,820
-91.0%
0.00%
-83.3%
Q1 2020$6,497,000
-53.1%
363,978
-43.3%
0.01%
-33.3%
Q4 2019$13,864,000
-27.2%
642,376
-38.6%
0.01%
-30.8%
Q3 2019$19,055,000
-57.6%
1,046,350
-17.1%
0.01%
-50.0%
Q2 2019$44,890,000
+149.7%
1,261,776
+135.7%
0.03%
+136.4%
Q1 2019$17,980,000
-42.2%
535,259
-43.5%
0.01%
-50.0%
Q4 2018$31,125,000
-48.9%
947,004
-5.2%
0.02%
+22.2%
Q3 2018$60,907,000
+29.5%
999,164
+3.7%
0.02%
+38.5%
Q2 2018$47,040,000
-23.0%
963,405
+67.5%
0.01%
-55.2%
Q1 2018$61,099,000
+176.5%
575,008
+55.4%
0.03%
+107.1%
Q4 2017$22,094,000
-27.2%
370,002
-70.8%
0.01%
-33.3%
Q3 2017$30,365,000
+199.7%
1,265,295
+144.1%
0.02%
+200.0%
Q2 2017$10,131,000
+158.2%
518,343
+209.9%
0.01%
+133.3%
Q1 2017$3,923,000
-44.1%
167,247
-70.8%
0.00%
-50.0%
Q4 2016$7,019,000
+27.4%
572,247
+78.4%
0.01%
+50.0%
Q3 2016$5,510,000
-40.9%
320,828
-51.0%
0.00%
-42.9%
Q2 2016$9,319,000
-22.0%
655,066
-24.6%
0.01%
-22.2%
Q1 2016$11,943,000
-32.6%
868,652
-17.4%
0.01%
-25.0%
Q4 2015$17,722,000
+455.7%
1,051,890
+261.4%
0.01%
+500.0%
Q3 2015$3,189,000
-13.6%
291,090
-1.4%
0.00%0.0%
Q2 2015$3,692,000
-23.7%
295,334
-32.9%
0.00%
-33.3%
Q1 2015$4,837,000
-15.2%
439,924
+19.5%
0.00%
-25.0%
Q4 2014$5,702,000
+75.7%
368,032
+36.8%
0.00%
+100.0%
Q3 2014$3,246,000
-13.5%
269,016
-8.2%
0.00%
-33.3%
Q2 2014$3,754,000
-20.4%
292,907
-24.8%
0.00%0.0%
Q1 2014$4,716,000
+21.3%
389,273
+13.6%
0.00%0.0%
Q4 2013$3,888,000
-33.5%
342,634
-38.8%
0.00%
-25.0%
Q3 2013$5,851,000560,3100.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2020
NameSharesValueWeighting ↓
Rhenman & Partners Asset Management AB 508,000$6,132,0001.80%
Bodri Capital Management, LLC 250,000$3,018,0001.46%
Granahan Investment Management 3,442,980$41,557,0001.28%
TIRSCHWELL & LOEWY INC 603,441$7,284,0001.22%
NEA Management Company, LLC 1,825,600$22,035,0001.12%
Cormorant Asset Management, LP 450,000$5,432,0001.12%
HARVEY CAPITAL MANAGEMENT INC 221,750$2,676,0001.05%
Cheyne Capital Management (UK) LLP 229,577$2,772,0000.99%
Artal Group S.A. 1,650,000$19,916,0000.73%
FIC CAPITAL INC 147,293$1,778,0000.71%
View complete list of NEKTAR THERAPEUTICS shareholders